The global genome editing market size is expected to reach USD 24.99 billion by 2030, exhibiting a CAGR of 17.8% from 2023 to 2030. The market is expected to expand at a CAGR of 17.8% from 2023 to 2030 The increasing advancements in genome editing technology, the growing funding & investments in the genomics industry, the increasing prevalence of genetic disorders, and the need for improved treatments and therapies are major factors driving revenue growth. ![Global Genome Editing Market]( "Global Genome Editing Market")
The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.
The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.
This product will be delivered within 1-3 business days.
The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.
The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.
Genome Editing Market Report Highlights
- By technology, the (CRISPR)/Cas9 segment held the highest share of 42.9% in 2022. It is due to an increased usage of CRISPR owing to its advantages such as targeted gene disruption
- Ex-vivo accounted for the dominant share of 52.6% in the delivery method segment in 2022. The dominant share is attributed to the growing high control offered by the model in DNA modification
- The genetic engineering segment dominated the global market in terms of application, due to the increasing number of gene therapy clinical trials
- By end-user, biotechnology and pharmaceutical companies segment held a major share of 51.2% in 2022 due to a growing number of research activities for novel therapeutic development within various biotechnology companies
- The contract-based segment dominated the market in 2022, due to the cost-effective services offered by contract service providers
- North America held a dominant share of 47.9% in 2022. The major reason is the presence of strong research, as well as a commercial base for advanced therapy development coupled with a high number of clinical trials being conducted for gene and stem cell therapies in the region
- A few of the key players include Merck KGaA; Cibus; Recombinetics, Inc.; Sangamo; Editas Medicine; Precision Biosciences; CRISPR Therapeutics; Intellia Therapeutics, Inc.; Caribou Biosciences, Inc.; Cellectis S. A.; AstraZeneca; Takara Bio USA; Horizon Discovery Group plc; Integrated DNA Technologies, Inc.; Egenesis Inc.; GenScript; New England Biolabs; and OriGene Technologies, Inc.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Success in pre-clinical models drives demands for genome editing therapeutics
3.4.2. Rising competition amongst market participants for business development
3.4.3. Easy editing solutions for the development of therapeutics for a broad range of diseases
3.4.4. Increasing demand for synthetic genes and genetically modified organisms
3.4.5. Technological advancements in gene editing technologies
3.4.6. Rising adoption in agricultural biotechnology
3.5. Market Restraint Analysis
3.5.1. Challenges concerning clinical translation
3.5.2. Regulatory, scientific, and ethical challenges regarding the use of genetically modified products
3.5.3. Off-target effects of CRISPR technology
3.6. Business Environment Analysis
3.7. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.8. Porter’s Five Forces Analysis
3.9. Genome Editing Technologies: Pipeline Analysis
3.9.1. Sangamo
3.9.2. Cellectis
3.9.3. Calyxt
3.9.4. bluebird bio
3.9.5. Editas Medicine
3.9.6. Intellia Therapeutics, Inc.
3.9.7. CRISPR Therapeutics
3.9.8. Precision Biosciences
3.9.9. Precision Biosciences (Non-medical domain)
3.9.10. Caribou Biosciences
3.9.11. Cibus
3.9.12. Recombinetics, Inc
3.10. Intellectual Property
3.11. Regulatory Issues
3.11.1. Orphan diseases
3.11.2. Germline editing
3.11.3. Safety issues
3.12. COVID-19 Impact Analysis
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Success in pre-clinical models drives demands for genome editing therapeutics
3.4.2. Rising competition amongst market participants for business development
3.4.3. Easy editing solutions for the development of therapeutics for a broad range of diseases
3.4.4. Increasing demand for synthetic genes and genetically modified organisms
3.4.5. Technological advancements in gene editing technologies
3.4.6. Rising adoption in agricultural biotechnology
3.5. Market Restraint Analysis
3.5.1. Challenges concerning clinical translation
3.5.2. Regulatory, scientific, and ethical challenges regarding the use of genetically modified products
3.5.3. Off-target effects of CRISPR technology
3.6. Business Environment Analysis
3.7. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.8. Porter’s Five Forces Analysis
3.9. Genome Editing Technologies: Pipeline Analysis
3.9.1. Sangamo
3.9.2. Cellectis
3.9.3. Calyxt
3.9.4. bluebird bio
3.9.5. Editas Medicine
3.9.6. Intellia Therapeutics, Inc.
3.9.7. CRISPR Therapeutics
3.9.8. Precision Biosciences
3.9.9. Precision Biosciences (Non-medical domain)
3.9.10. Caribou Biosciences
3.9.11. Cibus
3.9.12. Recombinetics, Inc
3.10. Intellectual Property
3.11. Regulatory Issues
3.11.1. Orphan diseases
3.11.2. Germline editing
3.11.3. Safety issues
3.12. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
4.1. Genome Editing Market: Technology Movement Analysis
4.2. Genome EditingTechnology Comparison
4.3. (CRISPR)/Cas9
4.3.1. Global (CRISPR)/Cas9 market, 2018 - 2030 (USD Million)
4.4. TALENs/MegaTALs
4.4.1. Global TALENs/MegaTALs market, 2018 - 2030 (USD Million)
4.5. ZFN
4.5.1. Global ZFN market, 2018 - 2030 (USD Million)
4.6. Meganucleases
4.6.1. Global Meganucleases market, 2018 - 2030 (USD Million)
4.7. Other Technologies
4.7.1. Global other technologies market, 2018 - 2030 (USD Million)
4.2. Genome EditingTechnology Comparison
4.3. (CRISPR)/Cas9
4.3.1. Global (CRISPR)/Cas9 market, 2018 - 2030 (USD Million)
4.4. TALENs/MegaTALs
4.4.1. Global TALENs/MegaTALs market, 2018 - 2030 (USD Million)
4.5. ZFN
4.5.1. Global ZFN market, 2018 - 2030 (USD Million)
4.6. Meganucleases
4.6.1. Global Meganucleases market, 2018 - 2030 (USD Million)
4.7. Other Technologies
4.7.1. Global other technologies market, 2018 - 2030 (USD Million)
Chapter 5. Delivery Method Business Analysis
5.1. Genome Editing Market: Delivery Method Movement Analysis
5.1.1. Comparison of Delivery Methods
5.1.1.1. Viral delivery
5.1.1.1.1. AAV (Adeno Associated Virus)
5.1.1.1.2. IDLV (Integrase Deficient Lentivirus).
5.1.1.2. Non-viral delivery
5.1.1.2.1. Lipid Mediated
5.1.1.2.2. Electroporation
5.2. Ex-vivo
5.2.1. Global ex-vivo delivery market, 2018 - 2030 (USD Million)
5.3. In-vivo
5.3.1. Global in-vivo delivery market, 2018 - 2030 (USD Million)
5.1.1. Comparison of Delivery Methods
5.1.1.1. Viral delivery
5.1.1.1.1. AAV (Adeno Associated Virus)
5.1.1.1.2. IDLV (Integrase Deficient Lentivirus).
5.1.1.2. Non-viral delivery
5.1.1.2.1. Lipid Mediated
5.1.1.2.2. Electroporation
5.2. Ex-vivo
5.2.1. Global ex-vivo delivery market, 2018 - 2030 (USD Million)
5.3. In-vivo
5.3.1. Global in-vivo delivery market, 2018 - 2030 (USD Million)
Chapter 6. Application Business Analysis
6.1. Genome Editing Market: Application Movement Analysis
6.2. Genetic Engineering
6.2.1. Genetic Engineering Market, 2018 - 2030 (USD Million)
6.2.1.1. Cell line engineering
6.2.1.1.1. Cell line engineering Market, 2018 - 2030 (USD Million)
6.2.1.2. Animal genetic engineering
6.2.1.2.1. Animal genetic engineering Market, 2018 - 2030 (USD Million)
6.2.1.3. Plant genetic engineering
6.2.1.3.1. Plant genetic engineering Market, 2018 - 2030 (USD Million)
6.2.1.4. Others
6.2.1.4.1. Global others market, 2018 - 2030 (USD Million)
6.3. Clinical Applications
6.3.1. Market for clinical applications, 2018 - 2030 (USD Million)
6.3.1.1. Diagnostics
6.3.1.1.1. Market for diagnostics applications, 2018 - 2030 (USD Million)
6.3.1.2. Therapy Development
6.3.1.2.1. Market for therapy development applications, 2018 - 2030 (USD Million)
6.2. Genetic Engineering
6.2.1. Genetic Engineering Market, 2018 - 2030 (USD Million)
6.2.1.1. Cell line engineering
6.2.1.1.1. Cell line engineering Market, 2018 - 2030 (USD Million)
6.2.1.2. Animal genetic engineering
6.2.1.2.1. Animal genetic engineering Market, 2018 - 2030 (USD Million)
6.2.1.3. Plant genetic engineering
6.2.1.3.1. Plant genetic engineering Market, 2018 - 2030 (USD Million)
6.2.1.4. Others
6.2.1.4.1. Global others market, 2018 - 2030 (USD Million)
6.3. Clinical Applications
6.3.1. Market for clinical applications, 2018 - 2030 (USD Million)
6.3.1.1. Diagnostics
6.3.1.1.1. Market for diagnostics applications, 2018 - 2030 (USD Million)
6.3.1.2. Therapy Development
6.3.1.2.1. Market for therapy development applications, 2018 - 2030 (USD Million)
Chapter 7. End-User Business Analysis
7.1. Genome Editing Market: End-User Movement Analysis
7.2. Biotechnology & Pharmaceutical Companies
7.2.1. Biotechnology & Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
7.3. Academic & Government Research Institutes
7.3.1. Academic & Government Research Institutes Market, 2018 - 2030 (USD Million)
7.4. Contract Research Organizations (CROs)
7.4.1. Contract Research Organizations (CROs) Market, 2018 - 2030 (USD Million)
7.2. Biotechnology & Pharmaceutical Companies
7.2.1. Biotechnology & Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
7.3. Academic & Government Research Institutes
7.3.1. Academic & Government Research Institutes Market, 2018 - 2030 (USD Million)
7.4. Contract Research Organizations (CROs)
7.4.1. Contract Research Organizations (CROs) Market, 2018 - 2030 (USD Million)
Chapter 8. Genome Editing Market: Mode Business Analysis
8.1. Genome Editing Market: Mode Movement Analysis
8.2. In-house
8.2.1. In-house Market, 2018 - 2030 (USD Million)
8.3. Contract
8.3.1. Contract Market, 2018 - 2030 (USD Million)
8.2. In-house
8.2.1. In-house Market, 2018 - 2030 (USD Million)
8.3. Contract
8.3.1. Contract Market, 2018 - 2030 (USD Million)
Chapter 9. Regional Business Analysis
9.1. Genome Editing Market Share By Region, 2022 & 2030
9.2. North America
9.2.1. SWOT Analysis
9.2.2. North America genome editing market, 2018 - 2030 (USD Million)
9.2.3. U.S.
9.2.3.1. Key Country Dynamics
9.2.3.2. Competitive Scenario
9.2.3.3. Regulatory Framework
9.2.3.4. Target Disease Prevalence
9.2.3.5. U.S. genome editing market, 2018 - 2030 (USD Million)
9.2.4. Canada
9.2.4.1. Key Country Dynamics
9.2.4.2. Competitive Scenario
9.2.4.3. Regulatory Framework
9.2.4.4. Target Disease Prevalence
9.2.4.5. Canada genome editing market, 2018 - 2030 (USD Million)
9.3. Europe
9.3.1. SWOT Analysis
9.3.2. Europe genome editing market, 2018 - 2030 (USD Million)
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Framework
9.3.3.4. Target Disease Prevalence
9.3.3.5. Germany genome editing market, 2018 - 2030 (USD Million)
9.3.4. UK
9.3.4.1. Key Country Dynamics
9.3.4.2. Competitive Scenario
9.3.4.3. Regulatory Framework
9.3.4.4. Target Disease Prevalence
9.3.4.5. UK genome editing market, 2018 - 2030 (USD Million)
9.3.5. France
9.3.5.1. Key Country Dynamics
9.3.5.2. Competitive Scenario
9.3.5.3. Regulatory Framework
9.3.5.4. Target Disease Prevalence
9.3.5.5. France genome editing market, 2018 - 2030 (USD Million)
9.3.6. Italy
9.3.6.1. Key Country Dynamics
9.3.6.2. Competitive Scenario
9.3.6.3. Regulatory Framework
9.3.6.4. Target Disease Prevalence
9.3.6.5. Italy genome editing market, 2018 - 2030 (USD Million)
9.3.7. Spain
9.3.7.1. Key Country Dynamics
9.3.7.2. Competitive Scenario
9.3.7.3. Regulatory Framework
9.3.7.4. Target Disease Prevalence
9.3.7.5. Spain genome editing market, 2018 - 2030 (USD Million)
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Competitive Scenario
9.3.8.3. Regulatory Framework
9.3.8.4. Target Disease Prevalence
9.3.8.5. Denmark genome editing market, 2018 - 2030 (USD Million)
9.3.9. Sweden
9.3.9.1. Key Country Dynamics
9.3.9.2. Competitive Scenario
9.3.9.3. Regulatory Framework
9.3.9.4. Target Disease Prevalence
9.3.9.5. Sweden genome editing market, 2018 - 2030 (USD Million)
9.3.10. Norway
9.3.10.1. Key Country Dynamics
9.3.10.2. Competitive Scenario
9.3.10.3. Regulatory Framework
9.3.10.4. Target Disease Prevalence
9.3.10.5. Norway genome editing market, 2018 - 2030 (USD Million)
9.4. Asia Pacific
9.4.1. SWOT Analysis
9.4.2. Asia Pacific genome editing market, 2018 - 2030 (USD Million)
9.4.3. Japan
9.4.3.1. Key Country Dynamics
9.4.3.2. Competitive Scenario
9.4.3.3. Regulatory Framework
9.4.3.4. Target Disease Prevalence
9.4.3.5. Japan genome editing market, 2018 - 2030 (USD Million)
9.4.4. China
9.4.4.1. Key Country Dynamics
9.4.4.2. Competitive Scenario
9.4.4.3. Regulatory Framework
9.4.4.4. Target Disease Prevalence
9.4.4.5. China genome editing market, 2018 - 2030 (USD Million)
9.4.5. India
9.4.5.1. Key Country Dynamics
9.4.5.2. Competitive Scenario
9.4.5.3. Regulatory Framework
9.4.5.4. Target Disease Prevalence
9.4.5.5. India genome editing market, 2018 - 2030 (USD Million)
9.4.6. South Korea
9.4.6.1. Key Country Dynamics
9.4.6.2. Competitive Scenario
9.4.6.3. Regulatory Framework
9.4.6.4. Target Disease Prevalence
9.4.6.5. South Korea genome editing market, 2018 - 2030 (USD Million)
9.4.7. Australia
9.4.7.1. Key Country Dynamics
9.4.7.2. Competitive Scenario
9.4.7.3. Regulatory Framework
9.4.7.4. Target Disease Prevalence
9.4.7.5. Australia genome editing market, 2018 - 2030 (USD Million)
9.4.8. Thailand
9.4.8.1. Key Country Dynamics
9.4.8.2. Competitive Scenario
9.4.8.3. Regulatory Framework
9.4.8.4. Target Disease Prevalence
9.4.8.5. Thailand genome editing market, 2018 - 2030 (USD Million)
9.5. Latin America
9.5.1. SWOT Analysis
9.5.2. Latin America genome editing market, 2018 - 2030 (USD Million)
9.5.3. Brazil
9.5.3.1. Key Country Dynamics
9.5.3.2. Competitive Scenario
9.5.3.3. Regulatory Framework
9.5.3.4. Target Disease Prevalence
9.5.3.5. Brazil genome editing market, 2018 - 2030 (USD Million)
9.5.4. Mexico
9.5.4.1. Key Country Dynamics
9.5.4.2. Competitive Scenario
9.5.4.3. Regulatory Framework
9.5.4.4. Target Disease Prevalence
9.5.4.5. Mexico genome editing market, 2018 - 2030 (USD Million)
9.5.5. Argentina
9.5.5.1. Key Country Dynamics
9.5.5.2. Competitive Scenario
9.5.5.3. Regulatory Framework
9.5.5.4. Target Disease Prevalence
9.5.5.5. Argentina genome editing market, 2018 - 2030 (USD Million)
9.6. MEA
9.6.1. SWOT Analysis
9.6.2. MEA genome editing market, 2018 - 2030 (USD Million)
9.6.3. South Africa
9.6.3.1. Key Country Dynamics
9.6.3.2. Competitive Scenario
9.6.3.3. Regulatory Framework
9.6.3.4. Target Disease Prevalence
9.6.3.5. South Africa genome editing market, 2018 - 2030 (USD Million)
9.6.4. Saudi Arabia
9.6.4.1. Key Country Dynamics
9.6.4.2. Competitive Scenario
9.6.4.3. Regulatory Framework
9.6.4.4. Target Disease Prevalence
9.6.4.5. Saudi Arabia genome editing market, 2018 - 2030 (USD Million)
9.6.5. UAE
9.6.5.1. Key Country Dynamics
9.6.5.2. Competitive Scenario
9.6.5.3. Regulatory Framework
9.6.5.4. Target Disease Prevalence
9.6.5.5. UAE genome editing market, 2018 - 2030 (USD Million)
9.6.6. Kuwait
9.6.6.1. Key Country Dynamics
9.6.6.2. Competitive Scenario
9.6.6.3. Regulatory Framework
9.6.6.4. Target Disease Prevalence
9.6.6.5. Kuwait genome editing market, 2018 - 2030 (USD Million)
9.2. North America
9.2.1. SWOT Analysis
9.2.2. North America genome editing market, 2018 - 2030 (USD Million)
9.2.3. U.S.
9.2.3.1. Key Country Dynamics
9.2.3.2. Competitive Scenario
9.2.3.3. Regulatory Framework
9.2.3.4. Target Disease Prevalence
9.2.3.5. U.S. genome editing market, 2018 - 2030 (USD Million)
9.2.4. Canada
9.2.4.1. Key Country Dynamics
9.2.4.2. Competitive Scenario
9.2.4.3. Regulatory Framework
9.2.4.4. Target Disease Prevalence
9.2.4.5. Canada genome editing market, 2018 - 2030 (USD Million)
9.3. Europe
9.3.1. SWOT Analysis
9.3.2. Europe genome editing market, 2018 - 2030 (USD Million)
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Framework
9.3.3.4. Target Disease Prevalence
9.3.3.5. Germany genome editing market, 2018 - 2030 (USD Million)
9.3.4. UK
9.3.4.1. Key Country Dynamics
9.3.4.2. Competitive Scenario
9.3.4.3. Regulatory Framework
9.3.4.4. Target Disease Prevalence
9.3.4.5. UK genome editing market, 2018 - 2030 (USD Million)
9.3.5. France
9.3.5.1. Key Country Dynamics
9.3.5.2. Competitive Scenario
9.3.5.3. Regulatory Framework
9.3.5.4. Target Disease Prevalence
9.3.5.5. France genome editing market, 2018 - 2030 (USD Million)
9.3.6. Italy
9.3.6.1. Key Country Dynamics
9.3.6.2. Competitive Scenario
9.3.6.3. Regulatory Framework
9.3.6.4. Target Disease Prevalence
9.3.6.5. Italy genome editing market, 2018 - 2030 (USD Million)
9.3.7. Spain
9.3.7.1. Key Country Dynamics
9.3.7.2. Competitive Scenario
9.3.7.3. Regulatory Framework
9.3.7.4. Target Disease Prevalence
9.3.7.5. Spain genome editing market, 2018 - 2030 (USD Million)
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Competitive Scenario
9.3.8.3. Regulatory Framework
9.3.8.4. Target Disease Prevalence
9.3.8.5. Denmark genome editing market, 2018 - 2030 (USD Million)
9.3.9. Sweden
9.3.9.1. Key Country Dynamics
9.3.9.2. Competitive Scenario
9.3.9.3. Regulatory Framework
9.3.9.4. Target Disease Prevalence
9.3.9.5. Sweden genome editing market, 2018 - 2030 (USD Million)
9.3.10. Norway
9.3.10.1. Key Country Dynamics
9.3.10.2. Competitive Scenario
9.3.10.3. Regulatory Framework
9.3.10.4. Target Disease Prevalence
9.3.10.5. Norway genome editing market, 2018 - 2030 (USD Million)
9.4. Asia Pacific
9.4.1. SWOT Analysis
9.4.2. Asia Pacific genome editing market, 2018 - 2030 (USD Million)
9.4.3. Japan
9.4.3.1. Key Country Dynamics
9.4.3.2. Competitive Scenario
9.4.3.3. Regulatory Framework
9.4.3.4. Target Disease Prevalence
9.4.3.5. Japan genome editing market, 2018 - 2030 (USD Million)
9.4.4. China
9.4.4.1. Key Country Dynamics
9.4.4.2. Competitive Scenario
9.4.4.3. Regulatory Framework
9.4.4.4. Target Disease Prevalence
9.4.4.5. China genome editing market, 2018 - 2030 (USD Million)
9.4.5. India
9.4.5.1. Key Country Dynamics
9.4.5.2. Competitive Scenario
9.4.5.3. Regulatory Framework
9.4.5.4. Target Disease Prevalence
9.4.5.5. India genome editing market, 2018 - 2030 (USD Million)
9.4.6. South Korea
9.4.6.1. Key Country Dynamics
9.4.6.2. Competitive Scenario
9.4.6.3. Regulatory Framework
9.4.6.4. Target Disease Prevalence
9.4.6.5. South Korea genome editing market, 2018 - 2030 (USD Million)
9.4.7. Australia
9.4.7.1. Key Country Dynamics
9.4.7.2. Competitive Scenario
9.4.7.3. Regulatory Framework
9.4.7.4. Target Disease Prevalence
9.4.7.5. Australia genome editing market, 2018 - 2030 (USD Million)
9.4.8. Thailand
9.4.8.1. Key Country Dynamics
9.4.8.2. Competitive Scenario
9.4.8.3. Regulatory Framework
9.4.8.4. Target Disease Prevalence
9.4.8.5. Thailand genome editing market, 2018 - 2030 (USD Million)
9.5. Latin America
9.5.1. SWOT Analysis
9.5.2. Latin America genome editing market, 2018 - 2030 (USD Million)
9.5.3. Brazil
9.5.3.1. Key Country Dynamics
9.5.3.2. Competitive Scenario
9.5.3.3. Regulatory Framework
9.5.3.4. Target Disease Prevalence
9.5.3.5. Brazil genome editing market, 2018 - 2030 (USD Million)
9.5.4. Mexico
9.5.4.1. Key Country Dynamics
9.5.4.2. Competitive Scenario
9.5.4.3. Regulatory Framework
9.5.4.4. Target Disease Prevalence
9.5.4.5. Mexico genome editing market, 2018 - 2030 (USD Million)
9.5.5. Argentina
9.5.5.1. Key Country Dynamics
9.5.5.2. Competitive Scenario
9.5.5.3. Regulatory Framework
9.5.5.4. Target Disease Prevalence
9.5.5.5. Argentina genome editing market, 2018 - 2030 (USD Million)
9.6. MEA
9.6.1. SWOT Analysis
9.6.2. MEA genome editing market, 2018 - 2030 (USD Million)
9.6.3. South Africa
9.6.3.1. Key Country Dynamics
9.6.3.2. Competitive Scenario
9.6.3.3. Regulatory Framework
9.6.3.4. Target Disease Prevalence
9.6.3.5. South Africa genome editing market, 2018 - 2030 (USD Million)
9.6.4. Saudi Arabia
9.6.4.1. Key Country Dynamics
9.6.4.2. Competitive Scenario
9.6.4.3. Regulatory Framework
9.6.4.4. Target Disease Prevalence
9.6.4.5. Saudi Arabia genome editing market, 2018 - 2030 (USD Million)
9.6.5. UAE
9.6.5.1. Key Country Dynamics
9.6.5.2. Competitive Scenario
9.6.5.3. Regulatory Framework
9.6.5.4. Target Disease Prevalence
9.6.5.5. UAE genome editing market, 2018 - 2030 (USD Million)
9.6.6. Kuwait
9.6.6.1. Key Country Dynamics
9.6.6.2. Competitive Scenario
9.6.6.3. Regulatory Framework
9.6.6.4. Target Disease Prevalence
9.6.6.5. Kuwait genome editing market, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Profiles/Listing
10.3.1. Merck KGaA
10.3.1.1. Overview
10.3.1.1.1. Sigma-Aldrich Co. LLC
10.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.1.3. Product Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Cibus
10.3.2.1. Overview
10.3.2.1.1. Nucelis
10.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.2.3. Product Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Recombinetics, Inc
10.3.3.1. Overview
10.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.3.3. Product Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Sangamo
10.3.4.1. Overview
10.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.4.3. Product Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Editas Medicine
10.3.5.1. Overview
10.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.5.3. Product Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Precision Biosciences
10.3.6.1. Overview
10.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.6.3. Product Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. CRISPR THERAPEUTICS
10.3.7.1. Overview
10.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.7.3. Product Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Intellia Therapeutics, Inc.
10.3.8.1. Overview
10.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.8.3. Product Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Caribou Biosciences, Inc
10.3.9.1. Overview
10.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.9.3. Product Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Cellectis
10.3.10.1. Overview
10.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.10.3. Product Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. AstraZeneca
10.3.11.1. Overview
10.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.11.3. Product Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Takara Bio Inc.
10.3.12.1. Overview
10.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.12.3. Product Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Horizon Discovery Group plc
10.3.13.1. Overview
10.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.13.3. Product Benchmarking
10.3.13.4. Strategic Initiatives
10.3.14. Integrated DNA Technologies, Inc.
10.3.14.1. Overview
10.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.14.3. Product Benchmarking
10.3.14.4. Strategic Initiatives
10.3.15. Transposagen Biopharmaceuticals, Inc.
10.3.15.1. Overview
10.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.15.3. Product Benchmarking
10.3.15.4. Strategic Initiatives
10.3.16. GenScript
10.3.16.1. Overview
10.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.16.3. Product Benchmarking
10.3.16.4. Strategic Initiatives
10.3.17. New England Biolabs
10.3.17.1. Overview
10.3.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.17.3. Product Benchmarking
10.3.17.4. Strategic Initiatives
10.3.18. OriGene Technologies, Inc.
10.3.18.1. Overview
10.3.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.18.3. Product Benchmarking
10.3.18.4. Strategic Initiatives
10.3.19. bluebird bio, Inc.
10.3.19.1. Overview
10.3.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.19.3. Product Benchmarking
10.3.19.4. Strategic Initiatives
10.3.20. Lonza
10.3.20.1. Overview
10.3.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.20.3. Product Benchmarking
10.3.20.4. Strategic Initiatives
10.3.21. Thermo Fisher Scientific, Inc.
10.3.21.1. Overview
10.3.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.21.3. Product Benchmarking
10.3.21.4. Strategic Initiatives
10.2. Strategy Mapping
10.3. Company Profiles/Listing
10.3.1. Merck KGaA
10.3.1.1. Overview
10.3.1.1.1. Sigma-Aldrich Co. LLC
10.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.1.3. Product Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Cibus
10.3.2.1. Overview
10.3.2.1.1. Nucelis
10.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.2.3. Product Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Recombinetics, Inc
10.3.3.1. Overview
10.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.3.3. Product Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Sangamo
10.3.4.1. Overview
10.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.4.3. Product Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Editas Medicine
10.3.5.1. Overview
10.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.5.3. Product Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Precision Biosciences
10.3.6.1. Overview
10.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.6.3. Product Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. CRISPR THERAPEUTICS
10.3.7.1. Overview
10.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.7.3. Product Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Intellia Therapeutics, Inc.
10.3.8.1. Overview
10.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.8.3. Product Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Caribou Biosciences, Inc
10.3.9.1. Overview
10.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.9.3. Product Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Cellectis
10.3.10.1. Overview
10.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.10.3. Product Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. AstraZeneca
10.3.11.1. Overview
10.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.11.3. Product Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Takara Bio Inc.
10.3.12.1. Overview
10.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.12.3. Product Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Horizon Discovery Group plc
10.3.13.1. Overview
10.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.13.3. Product Benchmarking
10.3.13.4. Strategic Initiatives
10.3.14. Integrated DNA Technologies, Inc.
10.3.14.1. Overview
10.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.14.3. Product Benchmarking
10.3.14.4. Strategic Initiatives
10.3.15. Transposagen Biopharmaceuticals, Inc.
10.3.15.1. Overview
10.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.15.3. Product Benchmarking
10.3.15.4. Strategic Initiatives
10.3.16. GenScript
10.3.16.1. Overview
10.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.16.3. Product Benchmarking
10.3.16.4. Strategic Initiatives
10.3.17. New England Biolabs
10.3.17.1. Overview
10.3.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.17.3. Product Benchmarking
10.3.17.4. Strategic Initiatives
10.3.18. OriGene Technologies, Inc.
10.3.18.1. Overview
10.3.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.18.3. Product Benchmarking
10.3.18.4. Strategic Initiatives
10.3.19. bluebird bio, Inc.
10.3.19.1. Overview
10.3.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.19.3. Product Benchmarking
10.3.19.4. Strategic Initiatives
10.3.20. Lonza
10.3.20.1. Overview
10.3.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.20.3. Product Benchmarking
10.3.20.4. Strategic Initiatives
10.3.21. Thermo Fisher Scientific, Inc.
10.3.21.1. Overview
10.3.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.21.3. Product Benchmarking
10.3.21.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 Global genome editing market, by technology, 2018 - 2030 (USD Million)
Table 3 Global genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 4 Global genome editing market, by application, 2018 - 2030 (USD Million)
Table 5 Global genome editing market, by mode, 2018 - 2030 (USD Million)
Table 6 Global genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 7 Global genome editing market, by region, 2018 - 2030 (USD Million)
Table 8 North America genome editing market, by country, 2018 - 2030 (USD Million)
Table 9 North America genome editing market, by technology, 2018 - 2030 (USD Million)
Table 10 North America genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 11 North America genome editing market, by application, 2018 - 2030 (USD Million)
Table 12 North America genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 13 North America genome editing market, by mode, 2018 - 2030 (USD Million)
Table 14 U.S. genome editing market, by technology, 2018 - 2030 (USD Million)
Table 15 U.S. genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 16 U.S. genome editing market, by application, 2018 - 2030 (USD Million)
Table 17 U.S. genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 18 U.S. genome editing market, by mode, 2018 - 2030 (USD Million)
Table 19 Canada genome editing market, by technology, 2018 - 2030 (USD Million)
Table 20 Canada genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 21 Canada genome editing market, by application, 2018 - 2030 (USD Million)
Table 22 Canada genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 23 Canada genome editing market, by mode, 2018 - 2030 (USD Million)
Table 24 Europe genome editing market, by country, 2018 - 2030 (USD Million)
Table 25 Europe genome editing market, by technology, 2018 - 2030 (USD Million)
Table 26 Europe genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 27 Europe genome editing market, by application, 2018 - 2030 (USD Million)
Table 28 Europe genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 29 Europe genome editing market, by mode, 2018 - 2030 (USD Million)
Table 30 Germany genome editing market, by technology, 2018 - 2030 (USD Million)
Table 31 Germany genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 32 Germany genome editing market, by application, 2018 - 2030 (USD Million)
Table 33 Germany genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 34 Germany genome editing market, by mode, 2018 - 2030 (USD Million)
Table 35 UK genome editing market, by technology, 2018 - 2030 (USD Million)
Table 36 UK genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 37 UK genome editing market, by application, 2018 - 2030 (USD Million)
Table 38 UK genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 39 UK genome editing market, by mode, 2018 - 2030 (USD Million)
Table 40 France genome editing market, by technology, 2018 - 2030 (USD Million)
Table 41 France genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 42 France genome editing market, by application, 2018 - 2030 (USD Million)
Table 43 France genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 44 France genome editing market, by mode, 2018 - 2030 (USD Million)
Table 45 Italy genome editing market, by technology, 2018 - 2030 (USD Million)
Table 46 Italy genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 47 Italy genome editing market, by application, 2018 - 2030 (USD Million)
Table 48 Italy genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 49 Italy genome editing market, by mode, 2018 - 2030 (USD Million)
Table 50 Spain genome editing market, by technology, 2018 - 2030 (USD Million)
Table 51 Spain genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 52 Spain genome editing market, by application, 2018 - 2030 (USD Million)
Table 53 Spain genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 54 Spain genome editing market, by mode, 2018 - 2030 (USD Million)
Table 55 Denmark genome editing market, by technology, 2018 - 2030 (USD Million)
Table 56 Denmark genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 57 Denmark genome editing market, by application, 2018 - 2030 (USD Million)
Table 58 Denmark genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 59 Denmark genome editing market, by mode, 2018 - 2030 (USD Million)
Table 60 Sweden genome editing market, by technology, 2018 - 2030 (USD Million)
Table 61 Sweden genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 62 Sweden genome editing market, by application, 2018 - 2030 (USD Million)
Table 63 Sweden genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 64 Sweden genome editing market, by mode, 2018 - 2030 (USD Million)
Table 65 Norway genome editing market, by technology, 2018 - 2030 (USD Million)
Table 66 Norway genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 67 Norway genome editing market, by application, 2018 - 2030 (USD Million)
Table 68 Norway genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 69 Norway genome editing market, by mode, 2018 - 2030 (USD Million)
Table 70 Asia Pacific genome editing market, by country, 2018 - 2030 (USD Million)
Table 71 Asia Pacific genome editing market, by technology, 2018 - 2030 (USD Million)
Table 72 Asia Pacific genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 73 Asia Pacific genome editing market, by application, 2018 - 2030 (USD Million)
Table 74 Asia Pacific genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 75 Asia Pacific genome editing market, by mode, 2018 - 2030 (USD Million)
Table 76 China genome editing market, by technology, 2018 - 2030 (USD Million)
Table 77 China genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 78 China genome editing market, by application, 2018 - 2030 (USD Million)
Table 79 China genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 80 China genome editing market, by mode, 2018 - 2030 (USD Million)
Table 81 Japan genome editing market, by technology, 2018 - 2030 (USD Million)
Table 82 Japan genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 83 Japan genome editing market, by application, 2018 - 2030 (USD Million)
Table 84 Japan genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 85 Japan genome editing market, by mode, 2018 - 2030 (USD Million)
Table 86 India genome editing market, by technology, 2018 - 2030 (USD Million)
Table 87 India genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 88 India genome editing market, by application, 2018 - 2030 (USD Million)
Table 89 India genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 90 India genome editing market, by mode, 2018 - 2030 (USD Million)
Table 91 South Korea genome editing market, by technology, 2018 - 2030 (USD Million)
Table 92 South Korea genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 93 South Korea genome editing market, by application, 2018 - 2030 (USD Million)
Table 94 South Korea genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 95 South Korea genome editing market, by mode, 2018 - 2030 (USD Million)
Table 96 Australia genome editing market, by technology, 2018 - 2030 (USD Million)
Table 97 Australia genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 98 Australia genome editing market, by application, 2018 - 2030 (USD Million)
Table 99 Australia genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 100 Australia genome editing market, by mode, 2018 - 2030 (USD Million)
Table 101 Thailand genome editing market, by technology, 2018 - 2030 (USD Million)
Table 102 Thailand genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 103 Thailand genome editing market, by application, 2018 - 2030 (USD Million)
Table 104 Thailand genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 105 Thailand genome editing market, by mode, 2018 - 2030 (USD Million)
Table 106 Latin America genome editing market, by country, 2018 - 2030 (USD Million)
Table 107 Latin America genome editing market, by technology, 2018 - 2030 (USD Million)
Table 108 Latin America genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 109 Latin America genome editing market, by application, 2018 - 2030 (USD Million)
Table 110 Latin America genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 111 Latin America genome editing market, by mode, 2018 - 2030 (USD Million)
Table 112 Brazil genome editing market, by technology, 2018 - 2030 (USD Million)
Table 113 Brazil genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 114 Brazil genome editing market, by application, 2018 - 2030 (USD Million)
Table 115 Brazil genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 116 Brazil genome editing market, by mode, 2018 - 2030 (USD Million)
Table 117 Mexico genome editing market, by technology, 2018 - 2030 (USD Million)
Table 118 Mexico genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 119 Mexico genome editing market, by application, 2018 - 2030 (USD Million)
Table 120 Mexico genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 121 Mexico genome editing market, by mode, 2018 - 2030 (USD Million)
Table 122 Argentina genome editing market, by technology, 2018 - 2030 (USD Million)
Table 123 Argentina genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 124 Argentina genome editing market, by application, 2018 - 2030 (USD Million)
Table 125 Argentina genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 126 Argentina genome editing market, by mode, 2018 - 2030 (USD Million)
Table 127 Middle East & Africa genome editing market, by country, 2018 - 2030 (USD Million)
Table 128 Middle East & Africa genome editing market, by technology, 2018 - 2030 (USD Million)
Table 129 Middle East & Africa genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 130 Middle East & Africa genome editing market, by application, 2018 - 2030 (USD Million)
Table 131 Middle East & Africa genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 132 Middle East & Africa genome editing market, by mode, 2018 - 2030 (USD Million)
Table 133 South Africa genome editing market, by technology, 2018 - 2030 (USD Million)
Table 134 South Africa genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 135 South Africa genome editing market, by application, 2018 - 2030 (USD Million)
Table 136 South Africa genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 137 South Africa genome editing market, by mode, 2018 - 2030 (USD Million)
Table 138 Saudi Arabia genome editing market, by technology, 2018 - 2030 (USD Million)
Table 139 Saudi Arabia genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia genome editing market, by application, 2018 - 2030 (USD Million)
Table 141 Saudi Arabia genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 142 Saudi Arabia genome editing market, by mode, 2018 - 2030 (USD Million)
Table 143 UAE genome editing market, by technology, 2018 - 2030 (USD Million)
Table 144 UAE genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 145 UAE genome editing market, by application, 2018 - 2030 (USD Million)
Table 146 UAE genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 147 Kuwait genome editing market, by technology, 2018 - 2030 (USD Million)
Table 148 Kuwait genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 149 Kuwait genome editing market, by application, 2018 - 2030 (USD Million)
Table 150 Kuwait genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 151 Kuwait genome editing market, by mode, 2018 - 2030 (USD Million)
Table 2 Global genome editing market, by technology, 2018 - 2030 (USD Million)
Table 3 Global genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 4 Global genome editing market, by application, 2018 - 2030 (USD Million)
Table 5 Global genome editing market, by mode, 2018 - 2030 (USD Million)
Table 6 Global genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 7 Global genome editing market, by region, 2018 - 2030 (USD Million)
Table 8 North America genome editing market, by country, 2018 - 2030 (USD Million)
Table 9 North America genome editing market, by technology, 2018 - 2030 (USD Million)
Table 10 North America genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 11 North America genome editing market, by application, 2018 - 2030 (USD Million)
Table 12 North America genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 13 North America genome editing market, by mode, 2018 - 2030 (USD Million)
Table 14 U.S. genome editing market, by technology, 2018 - 2030 (USD Million)
Table 15 U.S. genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 16 U.S. genome editing market, by application, 2018 - 2030 (USD Million)
Table 17 U.S. genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 18 U.S. genome editing market, by mode, 2018 - 2030 (USD Million)
Table 19 Canada genome editing market, by technology, 2018 - 2030 (USD Million)
Table 20 Canada genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 21 Canada genome editing market, by application, 2018 - 2030 (USD Million)
Table 22 Canada genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 23 Canada genome editing market, by mode, 2018 - 2030 (USD Million)
Table 24 Europe genome editing market, by country, 2018 - 2030 (USD Million)
Table 25 Europe genome editing market, by technology, 2018 - 2030 (USD Million)
Table 26 Europe genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 27 Europe genome editing market, by application, 2018 - 2030 (USD Million)
Table 28 Europe genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 29 Europe genome editing market, by mode, 2018 - 2030 (USD Million)
Table 30 Germany genome editing market, by technology, 2018 - 2030 (USD Million)
Table 31 Germany genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 32 Germany genome editing market, by application, 2018 - 2030 (USD Million)
Table 33 Germany genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 34 Germany genome editing market, by mode, 2018 - 2030 (USD Million)
Table 35 UK genome editing market, by technology, 2018 - 2030 (USD Million)
Table 36 UK genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 37 UK genome editing market, by application, 2018 - 2030 (USD Million)
Table 38 UK genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 39 UK genome editing market, by mode, 2018 - 2030 (USD Million)
Table 40 France genome editing market, by technology, 2018 - 2030 (USD Million)
Table 41 France genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 42 France genome editing market, by application, 2018 - 2030 (USD Million)
Table 43 France genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 44 France genome editing market, by mode, 2018 - 2030 (USD Million)
Table 45 Italy genome editing market, by technology, 2018 - 2030 (USD Million)
Table 46 Italy genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 47 Italy genome editing market, by application, 2018 - 2030 (USD Million)
Table 48 Italy genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 49 Italy genome editing market, by mode, 2018 - 2030 (USD Million)
Table 50 Spain genome editing market, by technology, 2018 - 2030 (USD Million)
Table 51 Spain genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 52 Spain genome editing market, by application, 2018 - 2030 (USD Million)
Table 53 Spain genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 54 Spain genome editing market, by mode, 2018 - 2030 (USD Million)
Table 55 Denmark genome editing market, by technology, 2018 - 2030 (USD Million)
Table 56 Denmark genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 57 Denmark genome editing market, by application, 2018 - 2030 (USD Million)
Table 58 Denmark genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 59 Denmark genome editing market, by mode, 2018 - 2030 (USD Million)
Table 60 Sweden genome editing market, by technology, 2018 - 2030 (USD Million)
Table 61 Sweden genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 62 Sweden genome editing market, by application, 2018 - 2030 (USD Million)
Table 63 Sweden genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 64 Sweden genome editing market, by mode, 2018 - 2030 (USD Million)
Table 65 Norway genome editing market, by technology, 2018 - 2030 (USD Million)
Table 66 Norway genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 67 Norway genome editing market, by application, 2018 - 2030 (USD Million)
Table 68 Norway genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 69 Norway genome editing market, by mode, 2018 - 2030 (USD Million)
Table 70 Asia Pacific genome editing market, by country, 2018 - 2030 (USD Million)
Table 71 Asia Pacific genome editing market, by technology, 2018 - 2030 (USD Million)
Table 72 Asia Pacific genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 73 Asia Pacific genome editing market, by application, 2018 - 2030 (USD Million)
Table 74 Asia Pacific genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 75 Asia Pacific genome editing market, by mode, 2018 - 2030 (USD Million)
Table 76 China genome editing market, by technology, 2018 - 2030 (USD Million)
Table 77 China genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 78 China genome editing market, by application, 2018 - 2030 (USD Million)
Table 79 China genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 80 China genome editing market, by mode, 2018 - 2030 (USD Million)
Table 81 Japan genome editing market, by technology, 2018 - 2030 (USD Million)
Table 82 Japan genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 83 Japan genome editing market, by application, 2018 - 2030 (USD Million)
Table 84 Japan genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 85 Japan genome editing market, by mode, 2018 - 2030 (USD Million)
Table 86 India genome editing market, by technology, 2018 - 2030 (USD Million)
Table 87 India genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 88 India genome editing market, by application, 2018 - 2030 (USD Million)
Table 89 India genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 90 India genome editing market, by mode, 2018 - 2030 (USD Million)
Table 91 South Korea genome editing market, by technology, 2018 - 2030 (USD Million)
Table 92 South Korea genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 93 South Korea genome editing market, by application, 2018 - 2030 (USD Million)
Table 94 South Korea genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 95 South Korea genome editing market, by mode, 2018 - 2030 (USD Million)
Table 96 Australia genome editing market, by technology, 2018 - 2030 (USD Million)
Table 97 Australia genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 98 Australia genome editing market, by application, 2018 - 2030 (USD Million)
Table 99 Australia genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 100 Australia genome editing market, by mode, 2018 - 2030 (USD Million)
Table 101 Thailand genome editing market, by technology, 2018 - 2030 (USD Million)
Table 102 Thailand genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 103 Thailand genome editing market, by application, 2018 - 2030 (USD Million)
Table 104 Thailand genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 105 Thailand genome editing market, by mode, 2018 - 2030 (USD Million)
Table 106 Latin America genome editing market, by country, 2018 - 2030 (USD Million)
Table 107 Latin America genome editing market, by technology, 2018 - 2030 (USD Million)
Table 108 Latin America genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 109 Latin America genome editing market, by application, 2018 - 2030 (USD Million)
Table 110 Latin America genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 111 Latin America genome editing market, by mode, 2018 - 2030 (USD Million)
Table 112 Brazil genome editing market, by technology, 2018 - 2030 (USD Million)
Table 113 Brazil genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 114 Brazil genome editing market, by application, 2018 - 2030 (USD Million)
Table 115 Brazil genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 116 Brazil genome editing market, by mode, 2018 - 2030 (USD Million)
Table 117 Mexico genome editing market, by technology, 2018 - 2030 (USD Million)
Table 118 Mexico genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 119 Mexico genome editing market, by application, 2018 - 2030 (USD Million)
Table 120 Mexico genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 121 Mexico genome editing market, by mode, 2018 - 2030 (USD Million)
Table 122 Argentina genome editing market, by technology, 2018 - 2030 (USD Million)
Table 123 Argentina genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 124 Argentina genome editing market, by application, 2018 - 2030 (USD Million)
Table 125 Argentina genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 126 Argentina genome editing market, by mode, 2018 - 2030 (USD Million)
Table 127 Middle East & Africa genome editing market, by country, 2018 - 2030 (USD Million)
Table 128 Middle East & Africa genome editing market, by technology, 2018 - 2030 (USD Million)
Table 129 Middle East & Africa genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 130 Middle East & Africa genome editing market, by application, 2018 - 2030 (USD Million)
Table 131 Middle East & Africa genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 132 Middle East & Africa genome editing market, by mode, 2018 - 2030 (USD Million)
Table 133 South Africa genome editing market, by technology, 2018 - 2030 (USD Million)
Table 134 South Africa genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 135 South Africa genome editing market, by application, 2018 - 2030 (USD Million)
Table 136 South Africa genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 137 South Africa genome editing market, by mode, 2018 - 2030 (USD Million)
Table 138 Saudi Arabia genome editing market, by technology, 2018 - 2030 (USD Million)
Table 139 Saudi Arabia genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia genome editing market, by application, 2018 - 2030 (USD Million)
Table 141 Saudi Arabia genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 142 Saudi Arabia genome editing market, by mode, 2018 - 2030 (USD Million)
Table 143 UAE genome editing market, by technology, 2018 - 2030 (USD Million)
Table 144 UAE genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 145 UAE genome editing market, by application, 2018 - 2030 (USD Million)
Table 146 UAE genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 147 Kuwait genome editing market, by technology, 2018 - 2030 (USD Million)
Table 148 Kuwait genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 149 Kuwait genome editing market, by application, 2018 - 2030 (USD Million)
Table 150 Kuwait genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 151 Kuwait genome editing market, by mode, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Genome editing market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
Fig. 13 Porter’s five forces analysis
Fig. 14 Genome editing market: Technology outlook key takeaways
Fig. 15 Genome editing market: Technology movement analysis
Fig. 16 Global (CRISPR)/Cas9market, 2018 - 2030 (USD Million)
Fig. 17 Global TALENs/MegaTALs market, 2018 - 2030 (USD Million)
Fig. 18 Global ZFN market, 2018 - 2030 (USD Million)
Fig. 19 Global meganucleases market, 2018 - 2030 (USD Million)
Fig. 20 Global other technologies market, 2018 - 2030 (USD Million)
Fig. 21 Genome editing market: Delivery method outlook key takeaways
Fig. 22 Genome editing market: Delivery method movement analysis
Fig. 23 Global ex-vivo delivery market, 2018 - 2030 (USD Million)
Fig. 24 Global in-vivo delivery market, 2018 - 2030 (USD Million)
Fig. 25 Genome editing market: Application outlook key takeaways
Fig. 26 Global genome editing market: Application movement analysis
Fig. 27 Global genetic engineering market, 2018 - 2030 (USD Million)
Fig. 28 Global cell line engineering/ gene therapy market, 2018 - 2030 (USD Million)
Fig. 29 Global animal genetic engineering market, 2018 - 2030 (USD Million)
Fig. 30 Global plant genetic engineering market, 2018 - 2030 (USD Million)
Fig. 31 Global other applications market, 2018 - 2030 (USD Million)
Fig. 32 Global clinical applications market, 2018 - 2030 (USD Million)
Fig. 33 Global diagnostic applications market, 2018 - 2030 (USD Million)
Fig. 34 Global therapy development applications market, 2018 - 2030 (USD Million)
Fig. 35 Genome editing market: End-use outlook key takeaways
Fig. 36 Global genome editing market: End-use movement analysis
Fig. 37 Global biotechnology & pharmaceutical companies market, 2018 - 2030 (USD Million)
Fig. 38 Global academic & government research institutes market, 2018 - 2030 (USD Million)
Fig. 39 Global CROs market, 2018 - 2030 (USD Million)
Fig. 40 Genome editing market: Mode outlook key takeaways
Fig. 41 Global genome editing market: Mode movement analysis
Fig. 42 Global in-house gene editing market, 2018 - 2030 (USD Million)
Fig. 43 Global contract gene editing market, 2018 - 2030 (USD Million)
Fig. 44 Regional marketplace: Key takeaway
Fig. 45 Genome editing regional outlook, 2020 & 2028
Fig. 46 Regional marketplace: key takeaways
Fig. 47 Regional outlook, 2022 & 2030
Fig. 48 Global genome editing market: region movement analysis
Fig. 49 North America genome editing market, 2018 - 2030 (USD Million)
Fig. 50 U.S. genome editing market, 2018 - 2030 (USD Million)
Fig. 51 Canada genome editing market, 2018 - 2030 (USD Million)
Fig. 52 Europe genome editing market, 2018 - 2030 (USD Million)
Fig. 53 Germany genome editing market, 2018 - 2030 (USD Million)
Fig. 54 UK genome editing market, 2018 - 2030 (USD Million)
Fig. 55 France genome editing market, 2018 - 2030 (USD Million)
Fig. 56 Italy genome editing market, 2018 - 2030 (USD Million)
Fig. 57 Spain genome editing market, 2018 - 2030 (USD Million)
Fig. 58 Denmark genome editing market, 2018 - 2030 (USD Million)
Fig. 59 Sweden genome editing market, 2018 - 2030 (USD Million)
Fig. 60 Norway genome editing market, 2018 - 2030 (USD Million)
Fig. 61 Asia Pacific genome editing market, 2018 - 2030 (USD Million)
Fig. 62 Japan genome editing market, 2018 - 2030 (USD Million)
Fig. 63 China genome editing market, 2018 - 2030 (USD Million)
Fig. 64 India genome editing market, 2018 - 2030 (USD Million)
Fig. 65 Australia genome editing market, 2018 - 2030 (USD Million)
Fig. 66 South Korea genome editing market, 2018 - 2030 (USD Million)
Fig. 67 Thailand genome editing market, 2018 - 2030 (USD Million)
Fig. 68 Latin America genome editing market, 2018 - 2030 (USD Million)
Fig. 69 Brazil genome editing market, 2018 - 2030 (USD Million)
Fig. 70 Mexico genome editing market, 2018 - 2030 (USD Million)
Fig. 71 Argentina genome editing market, 2018 - 2030 (USD Million)
Fig. 72 Middle East and Africa genome editing market, 2018 - 2030 (USD Million)
Fig. 73 South Africa genome editing market, 2018 - 2030 (USD Million)
Fig. 74 Saudi Arabia genome editing market, 2018 - 2030 (USD Million)
Fig. 75 UAE genome editing market, 2018 - 2030 (USD Million
Fig. 76 Kuwait genome editing market, 2018 - 2030 (USD Million)
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Genome editing market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
Fig. 13 Porter’s five forces analysis
Fig. 14 Genome editing market: Technology outlook key takeaways
Fig. 15 Genome editing market: Technology movement analysis
Fig. 16 Global (CRISPR)/Cas9market, 2018 - 2030 (USD Million)
Fig. 17 Global TALENs/MegaTALs market, 2018 - 2030 (USD Million)
Fig. 18 Global ZFN market, 2018 - 2030 (USD Million)
Fig. 19 Global meganucleases market, 2018 - 2030 (USD Million)
Fig. 20 Global other technologies market, 2018 - 2030 (USD Million)
Fig. 21 Genome editing market: Delivery method outlook key takeaways
Fig. 22 Genome editing market: Delivery method movement analysis
Fig. 23 Global ex-vivo delivery market, 2018 - 2030 (USD Million)
Fig. 24 Global in-vivo delivery market, 2018 - 2030 (USD Million)
Fig. 25 Genome editing market: Application outlook key takeaways
Fig. 26 Global genome editing market: Application movement analysis
Fig. 27 Global genetic engineering market, 2018 - 2030 (USD Million)
Fig. 28 Global cell line engineering/ gene therapy market, 2018 - 2030 (USD Million)
Fig. 29 Global animal genetic engineering market, 2018 - 2030 (USD Million)
Fig. 30 Global plant genetic engineering market, 2018 - 2030 (USD Million)
Fig. 31 Global other applications market, 2018 - 2030 (USD Million)
Fig. 32 Global clinical applications market, 2018 - 2030 (USD Million)
Fig. 33 Global diagnostic applications market, 2018 - 2030 (USD Million)
Fig. 34 Global therapy development applications market, 2018 - 2030 (USD Million)
Fig. 35 Genome editing market: End-use outlook key takeaways
Fig. 36 Global genome editing market: End-use movement analysis
Fig. 37 Global biotechnology & pharmaceutical companies market, 2018 - 2030 (USD Million)
Fig. 38 Global academic & government research institutes market, 2018 - 2030 (USD Million)
Fig. 39 Global CROs market, 2018 - 2030 (USD Million)
Fig. 40 Genome editing market: Mode outlook key takeaways
Fig. 41 Global genome editing market: Mode movement analysis
Fig. 42 Global in-house gene editing market, 2018 - 2030 (USD Million)
Fig. 43 Global contract gene editing market, 2018 - 2030 (USD Million)
Fig. 44 Regional marketplace: Key takeaway
Fig. 45 Genome editing regional outlook, 2020 & 2028
Fig. 46 Regional marketplace: key takeaways
Fig. 47 Regional outlook, 2022 & 2030
Fig. 48 Global genome editing market: region movement analysis
Fig. 49 North America genome editing market, 2018 - 2030 (USD Million)
Fig. 50 U.S. genome editing market, 2018 - 2030 (USD Million)
Fig. 51 Canada genome editing market, 2018 - 2030 (USD Million)
Fig. 52 Europe genome editing market, 2018 - 2030 (USD Million)
Fig. 53 Germany genome editing market, 2018 - 2030 (USD Million)
Fig. 54 UK genome editing market, 2018 - 2030 (USD Million)
Fig. 55 France genome editing market, 2018 - 2030 (USD Million)
Fig. 56 Italy genome editing market, 2018 - 2030 (USD Million)
Fig. 57 Spain genome editing market, 2018 - 2030 (USD Million)
Fig. 58 Denmark genome editing market, 2018 - 2030 (USD Million)
Fig. 59 Sweden genome editing market, 2018 - 2030 (USD Million)
Fig. 60 Norway genome editing market, 2018 - 2030 (USD Million)
Fig. 61 Asia Pacific genome editing market, 2018 - 2030 (USD Million)
Fig. 62 Japan genome editing market, 2018 - 2030 (USD Million)
Fig. 63 China genome editing market, 2018 - 2030 (USD Million)
Fig. 64 India genome editing market, 2018 - 2030 (USD Million)
Fig. 65 Australia genome editing market, 2018 - 2030 (USD Million)
Fig. 66 South Korea genome editing market, 2018 - 2030 (USD Million)
Fig. 67 Thailand genome editing market, 2018 - 2030 (USD Million)
Fig. 68 Latin America genome editing market, 2018 - 2030 (USD Million)
Fig. 69 Brazil genome editing market, 2018 - 2030 (USD Million)
Fig. 70 Mexico genome editing market, 2018 - 2030 (USD Million)
Fig. 71 Argentina genome editing market, 2018 - 2030 (USD Million)
Fig. 72 Middle East and Africa genome editing market, 2018 - 2030 (USD Million)
Fig. 73 South Africa genome editing market, 2018 - 2030 (USD Million)
Fig. 74 Saudi Arabia genome editing market, 2018 - 2030 (USD Million)
Fig. 75 UAE genome editing market, 2018 - 2030 (USD Million
Fig. 76 Kuwait genome editing market, 2018 - 2030 (USD Million)
Companies Mentioned
- Merck KGaA
- Cibus
- Recombinetics, Inc
- Sangamo
- Editas Medicine
- Precision Biosciences
- CRISPR THERAPEUTICS
- Intellia Therapeutics, Inc.
- Caribou Biosciences, Inc
- Cellectis
- AstraZeneca
- Takara Bio Inc.
- Horizon Discovery Group plc
- Integrated DNA Technologies, Inc.
- Transposagen Biopharmaceuticals, Inc.
- GenScript
- New England Biolabs
- OriGene Technologies, Inc.
- bluebird bio, Inc.
- Lonza
- Thermo Fisher Scientific, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | May 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 6.39 Billion |
| Forecasted Market Value ( USD | $ 24.99 Billion |
| Compound Annual Growth Rate | 17.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
